How Cisplatin Chemotherapy Works and Its Side Effects

Cisplatin is one of the most widely used and effective chemotherapy drugs ever developed, a platinum-based compound that kills cancer cells by damaging their DNA beyond repair. Approved in the late 1970s, it transformed testicular cancer from a near-certain death sentence into one of the most curable cancers in adults and remains a backbone treatment for ovarian, bladder, lung, and head and neck cancers. Its power comes with serious side effects, though, and understanding how cisplatin works, what it does to the body, and how oncologists manage its toxicity gives a clearer picture of modern cancer treatment than almost any other single drug.

How Cisplatin Kills Cancer Cells

Cisplatin is a small molecule built around a central platinum atom. Once it enters a cell, it sheds its chloride groups and binds directly to DNA, forming links between neighboring bases on the same strand. The most common of these links occurs between two adjacent guanine bases, creating what researchers call an intrastrand crosslink. That bond forces the DNA helix to bend sharply and partially unwind, distorting the double helix enough that the cell’s normal machinery can no longer read or copy it properly.¹ The crosslink also destabilizes the DNA structure itself, lowering its melting temperature and reducing its thermodynamic stability.²

When the cell detects this damage, it activates a cascade of stress responses. One of the earliest signals involves the protein p53, which gets activated and drives the cell toward programmed death.³ Cisplatin triggers multiple pathways that push cells to self-destruct. Computational modeling of these pathways has shown that the mitochondrial route, where the cell’s own energy-producing structures release signals that trigger death, is the most powerful of the three main apoptotic pathways cisplatin activates.⁴

Getting Inside the Cell

For years, researchers assumed cisplatin simply diffused through cell membranes because of its small size. It turns out the story is more interesting. Research in yeast and mammalian cells demonstrated that a copper transporter called CTR1 plays a major role in ferrying cisplatin into cells. When this transporter is deleted, cells take up far less cisplatin and become markedly more resistant to it.⁵ In cells completely lacking CTR1, accumulation of cisplatin dropped to roughly a third of normal levels.⁶ This discovery matters because it means anything that changes CTR1 levels on a tumor cell’s surface could affect how much drug gets in and, therefore, how well treatment works.

The Testicular Cancer Revolution

No discussion of cisplatin is complete without the story of testicular cancer, because it remains the single most dramatic success in the history of chemotherapy. Before cisplatin entered clinical trials in the mid-1970s, men with advanced testicular cancer had a cure rate of roughly five to ten percent.⁷ The initial combination of cisplatin, vinblastine, and bleomycin produced complete remissions in the majority of patients, with about 85 percent becoming disease-free, including some who needed surgery to remove residual masses after chemotherapy.⁸

Refinements followed. A later combination swapping vinblastine for etoposide (called BEP) proved less toxic and even more effective, becoming the standard regimen from 1984 onward. Today, over 90 percent of patients with standard-risk disseminated testicular cancer are cured, and even among those who relapse, roughly half can still be rescued with salvage chemotherapy. Overall, about 80 percent of all patients with metastatic testicular cancer survive their disease.⁹ That leap, from five percent survival to 80 percent, happened within a single generation of oncologists and remains unmatched by any other solid tumor.

Where Else Cisplatin Is Used

Cisplatin’s reach extends well beyond testicular cancer. It is one of the most commonly used anticancer drugs worldwide, with major roles in ovarian, bladder, and lung cancers.¹⁰ In head and neck cancers, cisplatin is routinely given alongside radiation therapy. Carboplatin, a related platinum drug with a gentler side-effect profile, has largely replaced cisplatin for ovarian tumors and non-small cell lung cancer in many settings, while oxaliplatin, a third-generation platinum agent, is the standard in colorectal cancer.¹¹ Each of these drugs works through similar DNA-binding chemistry but differs in which cancers respond best and which side effects predominate.

Why Cisplatin Makes You So Sick

Cisplatin’s side effects are among the most feared in oncology, and nausea and vomiting are often the first thing patients notice. Cisplatin is classified as highly emetogenic, meaning it causes vomiting in nearly all patients who receive it without anti-nausea drugs. The nausea occurs in two waves with distinct biology. In the first hours after treatment, the drug triggers cells lining the gut to release serotonin, which stimulates the brain’s vomiting center through the vagus nerve. Serotonin-blocking drugs are effective at controlling this acute phase.¹² After about eight to twelve hours, a delayed phase takes over in which substance P, a different chemical messenger, becomes the dominant trigger and requires a different class of anti-nausea medication to control.¹³ Modern anti-nausea regimens that combine drugs targeting both serotonin and substance P pathways have made cisplatin much more tolerable than it was in the 1980s, though it still ranks as one of the hardest chemotherapy drugs on the stomach.

Kidney Damage

Kidney toxicity is the side effect that most shapes how cisplatin is given. The drug concentrates in kidney tubule cells, partly because a transporter called OCT2 actively moves it from the blood into those cells. Research in mice showed that deleting the gene for OCT2 protected them from severe kidney damage without changing how much cisplatin was in the blood. In humans, a natural genetic variant in the OCT2 gene was linked to reduced kidney toxicity from cisplatin, confirming that this transporter plays a central role in why the kidneys are so vulnerable.¹⁴

In practice, every patient receiving cisplatin gets large volumes of intravenous saline before and after their infusion to flush the drug through the kidneys quickly and dilute its concentration in the tubules. Some centers add mannitol, a sugar alcohol that promotes urine flow, though the evidence on whether mannitol actually helps beyond saline alone is mixed.¹⁵ Kidney function is checked before every cycle, and if lab values show the kidneys are struggling, oncologists may reduce the dose, delay the next cycle, or switch to carboplatin, which is far less hard on the kidneys.

Hearing Loss

Cisplatin damages the delicate sensory cells of the inner ear, producing hearing loss that is bilateral, dose-dependent, progressive, and irreversible.¹⁶ High-frequency hearing goes first, which means many patients initially notice trouble hearing consonant sounds or following conversations in noisy environments. The loss can keep worsening even after treatment stops, because platinum remains embedded in inner-ear tissue for years.

This side effect is especially devastating in children. Pediatric studies report hearing loss in somewhere between 22 and 70 percent of treated children, with younger patients at higher risk: children diagnosed around age four or five tend to develop worse hearing loss than those diagnosed in their teens. Boys appear more vulnerable than girls, and cumulative dose is a consistent risk factor.¹⁷ Long-term follow-up of childhood cancer survivors found that roughly a third developed severe hearing loss, and those children were significantly more likely to experience speech and language delays, learning disabilities, and a need for special education, although interestingly, their self-reported quality of life scores on standardized questionnaires were not significantly lower overall.¹⁸

A protective agent called sodium thiosulfate has shown genuine promise. In a randomized trial, children who received sodium thiosulfate after cisplatin developed hearing loss at about half the rate of those who did not, roughly 29 percent versus 56 percent.¹⁹ A meta-analysis pooling multiple studies confirmed a roughly 40 percent reduction in the risk of hearing damage with sodium thiosulfate, without a significant worsening of cancer outcomes.²⁰ The main concern has been whether the protective agent might also shield tumor cells from cisplatin, but the data so far suggest it does not significantly hurt cancer control.

Nerve Damage

Cisplatin can cause peripheral neuropathy, a condition where the nerves in your hands and feet become damaged, leading to numbness, tingling, and sometimes pain. The severity of these symptoms tracks with how much platinum accumulates in the sensory nerve cell bodies in the spinal column, called dorsal root ganglia.²¹ Clinical studies using nerve conduction tests have shown that cisplatin causes degeneration of the large nerve cell bodies themselves, with loss of the longest nerve fibers first, which is why symptoms start in the toes and fingertips.²²

A distinct mechanism may also be at play. Cisplatin binds to DNA inside mitochondria with at least as much affinity as it binds to nuclear DNA, and it inhibits replication and transcription of mitochondrial genes. Treated nerve cells show visible mitochondrial damage and degradation, suggesting that cisplatin essentially starves these energy-hungry neurons of the capacity to power themselves.²³ Unlike nausea or low blood counts, neuropathy can persist long after treatment ends or even worsen for months afterward, a phenomenon sometimes called “coasting.” There is no widely accepted protective agent for cisplatin neuropathy, making dose management the primary strategy.

How Tumors Become Resistant

Cisplatin resistance is one of the biggest clinical problems in oncology. Many cancers that initially shrink with cisplatin eventually stop responding, and the mechanisms behind that resistance are varied. One well-studied route involves DNA repair. Cisplatin works by creating DNA damage that the cell cannot fix. If the cell ramps up its repair machinery, it can undo the damage before it triggers cell death. The gene ERCC1 is a key player here: in cisplatin-resistant ovarian cancer cells, ERCC1 was the only repair gene whose expression increased consistently across all levels of resistance.²⁴ Cisplatin itself can trigger higher ERCC1 expression through a signaling cascade, meaning the drug may inadvertently train surviving cells to resist it.²⁵

This has real clinical consequences. In non-small cell lung cancer, patients whose tumors lacked ERCC1 expression benefited significantly from cisplatin-based chemotherapy, while those whose tumors had high ERCC1 levels did not appear to benefit at all.²⁶ This finding has pushed researchers toward the idea of testing tumors for repair-gene status before choosing chemotherapy, though routine clinical use of such biomarkers is still evolving.

Resistance can also arise from changes in how the drug moves through the cell. In cisplatin-resistant ovarian cancer cells, the copper transporters ATP7A and ATP7B, which normally sit in a central cellular compartment, relocate to the cell’s periphery where they can shuttle cisplatin into small internal bubbles and then out of the cell before it ever reaches the nucleus.²⁷ In a sense, resistant cells learn to intercept and expel the drug using the same copper-handling equipment that the cell originally evolved to manage metal levels.

Cisplatin and Radiation Together

Cisplatin is frequently given alongside radiation therapy, especially for head and neck cancers, cervical cancer, and locally advanced lung cancer. This is not just a matter of attacking the tumor with two weapons at once; cisplatin actually makes cancer cells more vulnerable to radiation damage. One mechanism involves the cell’s ability to repair radiation-induced DNA breaks. Normally, cells stitch together broken DNA strands through a process called nonhomologous end joining. When a cisplatin-DNA lesion sits near the break site, it completely blocks this repair pathway, leaving the cell unable to fix the damage that radiation inflicts.²⁸

At an even more fundamental level, when radiation passes through DNA that has cisplatin attached to it, the platinum atom alters how low-energy electrons interact with the molecule. The drug changes the behavior of transient charged states in the DNA, increasing the likelihood that radiation-generated electrons will cause strand breaks. Cisplatin can even enable double-strand breaks at electron energies so low that they could not break both strands in unmodified DNA.²⁹ This synergy between the two treatments is why concurrent chemoradiation with cisplatin has become the standard of care in several cancer types.

Does the Time of Day Matter?

An intriguing and still-evolving area of cisplatin research involves chronotherapy, the idea that when you give the drug during the day affects both its toxicity and its effectiveness. In mice, evening administration led to faster clearance of cisplatin-DNA damage and less toxicity compared to morning administration, and this time-of-day difference disappeared in mice lacking functional circadian clock genes, confirming the link to the body’s internal clock.³⁰

Human data is limited but suggestive. A randomized trial in patients with advanced lung cancer found that those who received cisplatin in the evening (around 6:00 PM) experienced significantly lower rates of severe white blood cell drops and less gastrointestinal toxicity compared to those given the drug on a conventional morning schedule. Pharmacokinetic measurements showed that the body cleared cisplatin faster when it was given in the evening.³¹ The findings are provocative, but chronotherapy is not yet standard practice for cisplatin. Implementing it would require reorganizing infusion schedules and staffing patterns, and larger trials are needed to confirm whether the reduced toxicity translates into better cancer outcomes or just fewer side effects.

Nanoparticle Delivery

One of the most active research fronts for cisplatin involves wrapping it in nanoparticles to improve how it reaches tumors while sparing healthy tissue. The free drug distributes widely throughout the body, which is why so many organs get collateral damage. Nanoparticle formulations, including liposomes and polymer-based carriers, aim to exploit the fact that tumor blood vessels are leakier than normal vessels, allowing larger particles to accumulate preferentially in cancerous tissue.³²

A meta-analysis of nanocarrier-based cisplatin delivery found that encapsulated versions significantly reduced cancer cell survival, lowered the concentration needed to kill tumor cells, shrank tumor volumes, and importantly, reduced platinum accumulation in the kidneys compared to free cisplatin.³³ Several nanoparticle cisplatin formulations have entered clinical trials, though none has yet replaced the conventional drug in routine practice. The challenge is making particles that are stable in the bloodstream, release the drug at the right rate once they reach the tumor, and can be manufactured at scale.

The Access Problem

Cisplatin is on the World Health Organization’s Model List of Essential Medicines, and the drug itself is cheap to manufacture as a generic. Yet availability is uneven. In sub-Saharan Africa, researchers have documented stockouts of essential chemotherapy drugs including cisplatin at national hospitals, alongside pricing and quality concerns.³⁴ For a drug that can cure testicular cancer in the vast majority of cases and meaningfully extend life in several other cancers, supply-chain gaps represent a preventable source of cancer deaths. The drug’s requirement for aggressive hydration and monitoring also means it cannot simply be shipped to a clinic without the infrastructure to give it safely, a constraint that limits its use in resource-limited settings more than the cost of the drug itself.

1
PubMed Central. DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent ↩︎
2
PubMed. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex ↩︎
3
PubMed. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity ↩︎
4
PubMed Central. Computational modeling of apoptotic signaling pathways induced by cisplatin ↩︎
5
PubMed Central. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals ↩︎
6
Molecular Pharmacology. Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin ↩︎
7
PubMed. Treatment of testicular cancer: a new and improved model ↩︎
8
PubMed. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer ↩︎
9
PubMed Central. Curing metastatic testicular cancer ↩︎
10
PubMed Central. Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions ↩︎
11
ScienceDirect (Cancer Treatment Reviews). Molecular mechanisms of resistance and toxicity associated with platinating agents ↩︎
12
PubMed. A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective ↩︎
13
PubMed. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists ↩︎
14
PubMed Central. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity ↩︎
15
PubMed Central. The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: an ambispective cohort study ↩︎
16
PubMed Central. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies ↩︎
17
PubMed Central. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients ↩︎
18
PubMed Central. Quality of Life in Long-Term Survivors of Pediatric Cancer: The Impact of Hearing Loss ↩︎
19
PubMed Central. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial ↩︎
20
JAMA Network Open. Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis ↩︎
21
PubMed Central. Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response ↩︎
22
Brain. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies ↩︎
23
PubMed Central. Cisplatin induced Mitochondrial DNA Damage In Dorsal Root Ganglion Neurons ↩︎
24
Biochemical Pharmacology. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ercc1–xpf ↩︎
25
PubMed. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance ↩︎
26
PubMed. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy ↩︎
27
PubMed Central. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells ↩︎
28
PubMed Central. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining ↩︎
29
The Journal of Physical Chemistry C. Cisplatin Radiosensitization of DNA Irradiated with 2–20 eV Electrons: Role of Transient Anions ↩︎
30
PubMed Central. The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models ↩︎
31
PubMed. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis ↩︎
32
PubMed Central. Nanoparticle formulations of cisplatin for cancer therapy ↩︎
33
PubMed Central. Nanocarrier-mediated cancer therapy with cisplatin: A meta-analysis with a promising new paradigm ↩︎
34
PubMed Central / ASCO Publications (JCO Global Oncology). Chemotherapy Medications in Sub-Saharan Africa: Availability, Pricing, Affordability, and Predictors of Quality ↩︎